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EDITORIAL Open Access
The changing faces of migraine
Paolo Martelletti1* , Messoud Ashina2 and Lars Edvinsson3
Migraine represents today the crossroads of several scien-
tific evidences, such as lofty planetary prevalence, serious
disability, damaged quality of life, reduced productive
capacity, costly healthcare resulting in a creeping sentiment
of social stigma [1–3]. From the same crossroads, the
migraine paradigm as a multimorbid disease flows out [4]:
perhaps multi-systemic, however to be scanned and evalu-
ated at a distance as the horizon, in order to avoid the risk
of parcelling its real extent.
From before the triptans era, in less than 30 years we
have passed from the common acceptance of migraine
as an ineluctable family heredity to the evidence of a
complex genetic trait involving genomics, metabolomics
and, perhaps in the near future, also proteomics [5, 6].
In the meantime, the awareness of migraine as real
disease has been widespread in the general population and
even physicians’ education on migraine has made giant
steps forward at different levels of research, professionalism
and safe prescription [7–10].
Now that we are facing a new era, the Calcitonin Gene
Related Peptide (CGRP) one, with new perspectives and
hopes that only a new pharmacological class dedicated to
the prevention of migraine can offer, we must not forget
what has made this possible: solid and undisputable scien-
tific evidences acquired over the years first on animal and
then on human models [11, 12].
This topical collection helps us to orient the reader-
ship in the great mass of data that emerge from litera-
ture and systematize them in a series of comprehensive
reviews, progressively centered on chained topics. From
the classic burden of disease to the new acquisitions of
genetics, from the new pathophysiology CGRP-centered
of migraine to the description of the various new mole-
cules and their correct and safe therapeutic application,
up to the rocks of refractoriness and the unavoidable
ethical and economic need to identify the right patient
for the right drug using the precision medicine [13, 14].
Satisfied all the parameters, before the end of this path
we could have the chance to mark out the vanishing point
of migraine and to score the greatest try to be devoted to
each migraine patient.
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